heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-26. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
The current understanding of the drying conditions varies between different spray drying configurations and solution contents, but more research is being completed into the determination of what drives each particle shape pathways as future applications in pharmaceutical and industrial areas require better control over specific particle shapes and sizes of their products.
The degree of strictness of border controls varies across countries and borders. In some countries, controls may be targeted at the traveller's religion, ethnicity, nationality, or countries visited. Others may need to ensure the traveller has paid the appropriate fees for their visas and has future travel planned outside the country. Yet others may concentrate on the contents of the traveller's baggage and imported goods to ensure nothing is being carried that might pose a biosecurity risk to the country.
paracrine Describing or relating to a class of agonist signaling molecules produced and secreted by regulatory cells into the extracellular environment and then transported by passive diffusion to target cells other than those which produced them. The term may refer to the molecules themselves, sometimes called paramones, to the cells that produce them, or to signaling pathways which rely on them. Compare autocrine, endocrine, and juxtacrine.
=== Analogues === Retigabine is a bioisostere of flupirtine in which the pyridine ring has been replaced with a phenyl ring. Azetukalner (encukalner), pynegabine, and fluoxakalner are also analogues of flupirtine and retigabine.
Russia claimed to have taken the village of Umanske, 30 kilometers northwest of Donetsk. Russian officials claimed that nine people were injured in Ukrainian drone attacks and shelling in Belgorod and Kursk Oblasts.
Sources: en.wikipedia.org
Screening tests are offered to the asymptomatic people to reveal possible diseases. On the contrary, diagnostic tests are used to prove or disapprove certain conditions. To follow the course of the disease or the reaction to treatment, monitoring tests are presented. Lastly, there are tests during the follow-up to determine the results following treatment. The following is an example of a typical breakdown of the responsibilities of each area:
== Effectiveness == Silicone gel sheeting has remained the first-line therapy stated by international clinical recommendations on scar management. Scar measurements studied in most clinical trials include color (vascularisation and pigmentation), thickness (height: clinical and histological), relief (surface irregularities), pliability (tissue elasticity), and surface area (scar contraction or expansion). Scar elevation index is commonly used to indicate scar improvement. It measures the height of scar tissue compared to the normal surrounding skin. Studies show the effectiveness of silicone gel sheeting in minimizing scar elevation index. Another physical measure is the pliability of the scar tissue, which is also improved by silicone gel sheeting. Scar improvement is generally measured by size reduction, appearance, and calming effect. Silicone gel sheeting addresses the 3 requirements well among scar treatments. Several randomized controlled trials were carried out to assess the effectiveness. Silicone gel sheeting produces a statistically significant reduction in scar thickness and color amelioration. Therefore, it is an evidence-based non-invasive preventive treatment. Results of comparative studies on the effectiveness of silicone gel sheeting and silicone gel do not show significant differences between the two. Another non-invasive treatment is compression therapy, in which patients wear pressure garments to control the growth of scars. Pressure garments apply mechanical pressure to the surface of the scar, reducing the supply of blood and oxygen to the scar tissue.
"UNODC - Bulletin on Narcotics: The narcotic pepper - The chemistry and pharmacology of Piper methysticum and related species". United Nations Office on Drugs and Crime. 1973. pp. Issue 2. Retrieved 19 February 2014. Kava ban documents Piper methysticum information from the Hawaiian Ecosystems at Risk project (HEAR) "Kava" . Encyclopædia Britannica. Vol. 14 (9th ed.). 1882.
Former SNP chief executive Peter Murrell appears before Edinburgh Sheriff Court charged with embezzlement, while his estranged wife, former Nicola Sturgeon, is told she will face no further action in the police investigation into SNP finances. Kemi Badenoch launches the Conservative local election campaign at an event in Buckinghamshire. Jo Coburn announces her departure from the BBC and as host of the programme BBC Politics Live. The 2025 City of London Corporation election is held in the City of London. 21 March – SNP MSP Fergus Ewing announces he will not stand for the party at the 2026 Holyrood election, but may run as an independent. Leaked messages deepen the row between Nigel Farage and Rupert Lowe. Rachel Reeves pledges no "tax and spend" in her spring statement. 22 March – The UK government is reported to be considering establishing "return hubs" for failed asylum seekers in the Balkans. 23 March – Chancellor Rachel Reeves confirms plans to reduce government running costs by 15% by the end of the decade. Steve Witkoff, the US special envoy to the Middle East, dismisses Starmer's plan for an international peacekeeping force to support a ceasefire in Ukraine as "a posture and a pose". 25 March – The UK government confirms it is ending a contract with Stay Belvedere Hotels to provide places for asylum seekers after an audit identified concerns about the firm's performance. A report by Jacqueline Perry KC finds "credible evidence" Rupert Lowe and his staff mistreated two female team members in ways that "seem to amount to harassment".
Sources: en.wikipedia.org
=== Variable phenomena, invariant principle === According to the Paccaya sutta (SN 12.20 and its parallel in SA 296), dependent origination is the basic principle of conditionality which is at play in all conditioned phenomena. This principle is invariable and stable, while the "dependently arisen processes" (paṭiccasamuppannā dhammā) are variable and impermanent. Peter Harvey argues that there is an "overall Basic Pattern that is Dhamma" within which "specific basic patterns (dhammas) flow into and nurture each other in complex, but set, regular patterns.".
ImmTACs (Immune mobilising monoclonal T-cell receptors Against Cancer) are a class of bispecific biological drug being investigated for the treatment of cancer and viral infections which combines engineered cancer-recognizing TCRs with immune activating complexes. ImmTACs target cancerous or virally infected cells through binding human leukocyte antigen (HLA) presented peptide antigens and redirect the host's cytotoxic T cells to recognise and kill them. ImmTACs are fusion proteins that combine an engineered T Cell Receptor (TCR) based targeting system with a single chain antibody fragment (scFv) effector function. TCRs, like antibodies, constitute an important antigen recognition system within the immune system; but, whereas antibodies are restricted to targeting cell surface or secreted proteins TCRs can recognise peptides derived from intracellular targets presented by human leukocyte antigen (HLA). Naturally occurring TCRs are low affinity (0.18-387 micromolar range) 2-chain membrane receptors expressed on the surface of T cells. To produce stable, soluble, high affinity TCRs capable of being used as diagnostics and therapeutics the two TCR protein chains are stabilised through the introduction of a novel disulphide bond between the 2 constant domains and the affinity increased 1-5 million fold to low picomolar values through phage display affinity maturation. To provide the soluble, affinity enhanced TCR with a biological effector function the beta chain of the TCR is fused to an scFv antibody fragment specific for the CD3 T cell co-receptor, creating an ImmTAC.
Gonadotropin-releasing hormone antagonists (GnRH antagonists) are a class of medications that antagonize the gonadotropin-releasing hormone receptor (GnRH receptor) and thus the action of gonadotropin-releasing hormone (GnRH). They are used in the treatment of prostate cancer, endometriosis, uterine fibroids, female infertility in assisted reproduction, and for other indications. Some GnRH antagonists, such as cetrorelix, are similar in structure to natural GnRH (a hormone made by neurons in the hypothalamus) but have an antagonistic effect, while other GnRH antagonists, such as elagolix and relugolix, are non-peptide and small-molecule compounds. GnRH antagonists compete with natural GnRH for binding to GnRH receptors, thus decreasing or blocking GnRH action in the body.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
Each freeze-thaw cycle can degrade a fraction of the peptide and promote aggregation. Dividing a stock solution into single-use volumes removes repeated cycling as a variable. It also limits the time a thawed solution spends at room temperature.